An Overview of Isavuconazole Clinical Use: A Multicentre Analysis of Indications, Exposure and Hepatic Safety
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background Isavuconazole is a recent broad-spectrum triazole indicated for the treatment of invasive aspergillosis and mucormycosis when amphotericin B is inappropriate. However, limited information exists on its clinical use. Objective We set up a retrospective multicentre study to describe the clinical practice of isavuconazole including indications, exposure, and hepatic safety. Methods From January 2021 to June 2023, all patients who received isavuconazole and had at least one therapeutic drug monitoring (TDM) measurement, were included. To identify independent predictors of isavuconazole trough concentrations (Cmin), linear regression analyses were performed. Causal relationship between the occurrence of liver injury and isavuconazole was also analysed. Results Most of the included patients (n = 102) were admitted into haematology units (41.1% [n = 42]) or intensive care units (ICU) (30.4% [n = 31]). Aspergillosis (47.0% [n = 48]), mucormycosis (25.6% [n = 26]), and off-label empirical treatments (18.6% [n = 19]), were the three most common indications. About half of the patients (46.1% [n = 47]) had an optimal exposure, while 42.2% (n = 43) were underexposed, and 11.7% (n = 12) were overexposed. Albumin level on the day of TDM was a significant factor associated with an increase in isavuconazole Cmin (p = 0.010). Among the 11 patients who had liver test abnormalities, isavuconazole was discontinued in six (n = 6) patients and liver injury was attributable to isavuconazole in two (n = 2) patients. Conclusions This multicentre analysis highlighted the common use of isavuconazole as an off-label indication, as well as the frequent underexposure of patients to isavuconazole. Albumin on the day of TDM appeared to be an important factor driving isavuconazole exposure, especially in ICU patients.
Source: Clinical Drug Investigation
Authors: Anne-Lise Bienvenu, Alexandra Duffour, Claire Chatron, Natacha Mrozek, Luc Foroni, Aurélien Millet, Anne-Claire Lukaszewicz, Claire Merveilleux-du-Vignaux, Philippe Portran, François Parant, Thierry Vial, Hélène Labussière-Wallet, Cécile Moluçon-Chabrot, Pauline Rascle, Agnès Henry, Pierre Pradat, Sylvain Goutelle
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,190
OpenAlex ID: W4408972851
